Combination antiretroviral therapy. Back to the future.

Abstract:

:HIV causes chronic infection and is associated with persistent viral replication and a high viral mutation rate. It is an illusion to think that monotherapy with any antiretroviral agent will have a major and lasting impact on this disease. Monotherapy with antitubercular agents led to dramatic improvements in treatment, but the development of drug resistance meant that these improvements were of only short duration, and hence it was concluded that drugs should be combined. The response to the limited efficacy of nucleoside analogue monotherapy in HIV infection has in many instances been the stance that 'currently available antiretrovirals are no good; it is better not to treat'. In addition, regulatory insistence on clinical end-points has also hampered antiretroviral drug development. It is implied that antiretrovirals must be tested in populations with fairly advanced HIV infection, in whom the least success may be expected. The regulatory bind has also resulted in artificial and counterproductive treatment guidelines. Common sense and experience in infectious diseases dictate that treatment should hit hard and early. No study published thus far undermines the concept that early therapy is better than late therapy or that a tolerable combination of drugs with additive or synergistic anti-HIV activity is better than nucleoside monotherapy. Promising data have been generated in trials on combinations of zidovudine plus didanosine or zalcitabine; a combination of zidovudine and lamivudine (3TC) may be even more promising.(ABSTRACT TRUNCATED AT 250 WORDS)

journal_name

Drugs

journal_title

Drugs

authors

Lange J

doi

10.2165/00003495-199500491-00008

subject

Has Abstract

pub_date

1995-01-01 00:00:00

pages

32-7; discussion 38-40

eissn

0012-6667

issn

1179-1950

journal_volume

49 Suppl 1

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.

    abstract::In a double-blind study, 128 patients with essential hypertension, refractory to beta-blocker monotherapy, were randomised to 1 of 4 treatment groups. Felodipine 2.5 mg twice daily, 5mg twice daily, 10mg twice daily or matched placebo twice daily were administered in addition to the beta-blocker for 4 weeks. Mean supi...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700343-00023

    authors: Sluiter HE

    更新日期:1987-01-01 00:00:00

  • Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.

    abstract::Gefitinib (Iressa) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that offers treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in particular in those who are harbouring EGFR mutations. In a large phase III trial (IPASS) in chemotherapy-naive Asian ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/10489100-000000000-00000

    authors: Sanford M,Scott LJ

    更新日期:2009-11-12 00:00:00

  • Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

    abstract::Specifically formulated for nebulisation using the PARI LC PLUS reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients with cystic fibrosis, while maintaining low...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363220-00015

    authors: Cheer SM,Waugh J,Noble S

    更新日期:2003-01-01 00:00:00

  • Tenapanor: First Approval.

    abstract::The selective sodium hydrogen exchanger 3 (NHE3) inhibitor tenapanor is being developed by Ardelyx Inc. for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) [under the tradename IBSRELA®] and for hyperphosphataemia in patients with chronic kidney disease (CKD) on dialysis or with end stage re...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01215-9

    authors: Markham A

    更新日期:2019-11-01 00:00:00

  • Levetiracetam: a review of its use in epilepsy.

    abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizu...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11204490-000000000-00000

    authors: Lyseng-Williamson KA

    更新日期:2011-03-05 00:00:00

  • Guillain-Barré syndrome: epidemiology, pathophysiology and management.

    abstract::Guillain-Barré syndrome (GBS) is clinically defined as an acute peripheral neuropathy causing limb weakness that progresses over a time period of days or, at the most, up to 4 weeks. GBS occurs throughout the world with a median annual incidence of 1.3 cases per population of 100 000, with men being more frequently af...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464060-00003

    authors: Kuwabara S

    更新日期:2004-01-01 00:00:00

  • Are All Dopamine Agonists Essentially the Same?

    abstract::Dopamine agonists (DAs) represent an excellent treatment option for patients with Parkinson's disease, in both the early and advanced stages of the disease, improving motor symptoms, lowering the incidence of motor complications, and addressing several non-motor symptoms. Indeed, each of these compounds have different...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01103-2

    authors: Torti M,Bravi D,Vacca L,Stocchi F

    更新日期:2019-05-01 00:00:00

  • Management of Thrombotic Complications in COVID-19: An Update.

    abstract::Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01377-x

    authors: Hajra A,Mathai SV,Ball S,Bandyopadhyay D,Veyseh M,Chakraborty S,Lavie CJ,Aronow WS

    更新日期:2020-10-01 00:00:00

  • Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

    abstract:UNLABELLED:Patients with beta-thalassaemia and other transfusion-dependent diseases develop iron overload from chronic blood transfusions and require regular iron chelation to prevent potentially fatal iron-related complications. The only iron chelator currently widely available is deferoxamine, which is expensive and ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958030-00021

    authors: Barman Balfour JA,Foster RH

    更新日期:1999-09-01 00:00:00

  • Endothelial function. General considerations.

    abstract::The endothelium is involved in both the physiological regulation of vascular tone and the structural transformation of the vessel under pathological conditions. Under physiological conditions, endothelial cells continuously secrete nitric oxide (NO), which relaxes smooth muscle cells and ensures vessel patency. Damage...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700531-00003

    authors: Haller H

    更新日期:1997-01-01 00:00:00

  • Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

    abstract::Bisoprolol is a beta 1-adrenoceptor antagonist with no partial agonist (intrinsic sympathomimetic) activity or membrane stabilising (local anaesthetic) activity. The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198836030-00002

    authors: Lancaster SG,Sorkin EM

    更新日期:1988-09-01 00:00:00

  • The role of anaerobic bacteria in mediastinitis.

    abstract::The management of mediastinitis involves directing appropriate antibacterial therapy against the potential bacterial pathogens. The increased recovery of anaerobic bacteria from mediastinal infections has led to a greater appreciation of their role in this condition and to re-evaluation of the proper treatment of this...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666030-00004

    authors: Brook I

    更新日期:2006-01-01 00:00:00

  • Oxantel-pyrantel in various regimens for the treatment of soil transmitted helminthiasis in rural and urban communities.

    abstract::204 individuals from a rural community were given a single dose of oxantel-pyrantel at 15mg/kg bodyweight and if still infected, 20mg/kg bodyweight, with cure rates of 100%, 53% and 71% for ascariasis, trichuriasis and hookworm infection, respectively. From an urban community, 124 patients were given the same drug eit...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-197800151-00016

    authors: Cabrera BD,Sy FS

    更新日期:1978-01-01 00:00:00

  • Desirable therapeutic characteristics of an optimal antihypertensive agent.

    abstract::Hypertension affects 65 million people in the US, and is a major cause of morbidity and mortality, but less than one-third of patients with hypertension are treated to goal blood pressure. Multiple factors have been cited, and include suboptimal adherence to treatment and lifestyle modifications, limited access to hea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666090-00006

    authors: Mustone Alexander L

    更新日期:2006-01-01 00:00:00

  • Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus.

    abstract::In type 1 and 2 diabetes mellitus patients, hyperglycaemia is independently related to the development of microvascular and macrovascular complications. Glycaemic targets and the benefits of intensive versus conventional glucose control are under debate. The purpose of this review is to provide an overview of the rand...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11585220-000000000-00000

    authors: Mattila TK,de Boer A

    更新日期:2010-12-03 00:00:00

  • Quinidine and digoxin. An important interaction.

    abstract::An increase in serum digoxin concentration occurs in 90% of patients given quinidine. On average, the serum digoxin doubles during treatment with therapeutic doses of quinidine. Almost every patient treated with quinidine will have a decrease in the renal clearance of digoxin and many will have a decrease in the volum...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224030-00003

    authors: Bigger JT Jr,Leahey EB Jr

    更新日期:1982-09-01 00:00:00

  • Durability and rapidity of response to anakinra in patients with rheumatoid arthritis.

    abstract::Rheumatoid arthritis (RA) is a chronic and progressive inflammatory disease that ultimately leads to disability and functional decline. Because patients usually develop RA in mid-life, they may experience its consequences for 20-30 years or longer. Proinflammatory cytokines, notably interleukin (IL)-1 and tumour necro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464220-00001

    authors: Schiff MH

    更新日期:2004-01-01 00:00:00

  • Treatment of Kaposi's sarcoma. Current guidelines and future perspectives.

    abstract::Kaposi's sarcoma is the most common malignancy associated with HIV infection, and the morbidity and mortality attributable to AIDS-related Kaposi's sarcoma (AIDS-KS) may be increasing. No curative therapy is available for AIDS-KS, but palliative therapy can eliminate or reduce cosmetically unacceptable lesions, reduce...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199448040-00006

    authors: Northfelt DW

    更新日期:1994-10-01 00:00:00

  • The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.

    abstract::The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0565-4

    authors: Seiler T,Hutter G,Dreyling M

    更新日期:2016-04-01 00:00:00

  • Drugs in the treatment of female infertility. Recent advances.

    abstract::Involuntary infertility is an increasing problem in this era of delayed childbearing. Fortunately, many advances have been made recently in the medical and surgical treatment of infertility. This article reviews the principal aetiologies of infertility and their treatments, and focuses on the current and future uses o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198632020-00004

    authors: Quigley MM

    更新日期:1986-08-01 00:00:00

  • Therapeutic experience with temocillin in peritonitis.

    abstract::The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. Patients were treated with temocillin Ig intravenously twice daily. The isolated pathogens comprised mainly Escherichia co...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00042

    authors: Pfeiffer M,Fock RR

    更新日期:1985-01-01 00:00:00

  • Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

    abstract::Tenoxicam is a new non-steroidal anti-inflammatory and analgesic agent of the oxicam class, and therefore closely related to piroxicam. It possesses a long half-life which enables it to be administered once daily. Clinical trials in patients with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout and n...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198734030-00001

    authors: Gonzalez JP,Todd PA

    更新日期:1987-09-01 00:00:00

  • Balanced analgesia: what is it and what are its advantages in postoperative pain?

    abstract::The concept of balanced analgesia was introduced to improve analgesic efficacy and reduce adverse effects. A large amount of clinical data has documented improved analgesia by combining different analgesics, but data on reducing adverse effects are inconclusive. Balanced analgesia should be used whenever possible, and...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958050-00002

    authors: Kehlet H,Werner M,Perkins F

    更新日期:1999-11-01 00:00:00

  • Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection.

    abstract::Rheumatoid arthritis is a disease of unknown aetiology characterised by persistent joint swelling, functional disability and increased mortality. No curative therapy exists at present but some therapeutic agents, commonly referred to as disease-modifying drugs, offer the potential for suppression of the inflammatory a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856030-00003

    authors: Jackson CG,Williams HJ

    更新日期:1998-09-01 00:00:00

  • Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

    abstract:UNLABELLED:Oral delayed-release mesalazine is an enteric-coated formulation which releases mesalazine in the terminal ileum and colon. Up to 74% of patients with mild to moderately active ulcerative colitis experience endoscopic or symptomatic improvement (including remission) or both when treated with oral delayed-rel...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957030-00013

    authors: Prakash A,Markham A

    更新日期:1999-03-01 00:00:00

  • Antibiotics in neonatal infections: a review.

    abstract::The bacteria most commonly responsible for early-onset (materno-fetal) infections in neonates are group B streptococci, enterococci, Enterobacteriaceae and Listeria monocytogenes. Coagulase-negative staphylococci, particularly Staphylococcus epidermidis, are the main pathogens in late-onset (nosocomial) infections, es...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958030-00003

    authors: Fanos V,Dall'Agnola A

    更新日期:1999-09-01 00:00:00

  • Phentermine and topiramate extended release (Qsymia™): first global approval.

    abstract::Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight los...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11640860-000000000-00000

    authors: Cameron F,Whiteside G,McKeage K

    更新日期:2012-10-22 00:00:00

  • Pharmacotherapy for oesophagogastric cancer.

    abstract::Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease. The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767170-00006

    authors: Jackson C,Starling N,Chua YJ,Cunningham D

    更新日期:2007-01-01 00:00:00

  • Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain.

    abstract::Increases in cancer diagnosis have tremendous negative impacts on patients and their families, and major societal and economic costs. The beneficial effect of chemotherapeutic agents on tumor suppression comes with major unwanted side effects such as weight and hair loss, nausea and vomiting, and neuropathic pain. Che...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01132-x

    authors: Blanton HL,Brelsfoard J,DeTurk N,Pruitt K,Narasimhan M,Morgan DJ,Guindon J

    更新日期:2019-06-01 00:00:00

  • Temocillin concentrations in human tissues.

    abstract::67 samples of 15 different tissues were obtained from 26 patients who were given an intravenous bolus dose of temocillin approximately 3 to 4 hours prior to surgery. 50 tissue samples were obtained from 19 patients who received 1g temocillin and 17 tissue samples were obtained from 7 patients who received 2g temocilli...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198500295-00034

    authors: Gould JG,Meikle G,Cooper DL,Horton R

    更新日期:1985-01-01 00:00:00